EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Aug. 17, 2006--Dutton Associates updates its coverage of Applied NeuroSolutions, Inc. (OTCBB:APNS) maintaining a Speculative Buy rating. The 12-page report by Dutton senior analyst Denise T. Resnik, M.S. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
We believe Applied NeuroSolutions Inc. is at a juncture where the Company's promising intellectual property in the understanding of Alzheimer's disease is attracting an increasing level of interest within the health care field. Applied NeuroSolutions' work is still at the development stage, and while the Company must contend with inadequate current funding, we believe that, at the current price, the Company's shares provide an opportunity for substantial capital gains if it is able to consummate collaborative agreements in the coming year that strengthen its finances and provide additional validation of its science. In recent years, the cause and treatment of AD was believed to be related to amyloid protein formation and deposition. However, despite years of amyloid protein research, amyloids have not proven to be directly related to the etiology of AD. More recent research has focused on a different brain protein, known as tau. Applied NeuroSolutions has identified tau as a biomarker for AD and is investigating mechanisms and pathways of precursors of both tau and amyloid proteins.
About Dutton Associates
Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid before commencement of our research activities. We received $33,000 from the Company for 4 quarterly Research Reports with coverage commencing on 06/28/2005. Our principals and analysts do not own or trade the securities of this company. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
